P2RY12 and COVID-19: Berger et al. conducted a randomized clinical study with 562 noncritically ill patients admitted for COVID-19 to assess the benefits and risks of adding a P2Y12 inhibitor (clopidogrel was used in 37% and ticagrelor in 63%) to anticoagulant therapy among hospitalized noncritically ill COVID-19 patients.